Duality Advisers LP Purchases New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Duality Advisers LP acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,346 shares of the medical equipment provider’s stock, valued at approximately $606,000.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Lantheus by 4.4% in the third quarter. Vanguard Group Inc. now owns 7,765,120 shares of the medical equipment provider’s stock valued at $546,121,000 after buying an additional 326,396 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Lantheus by 18.1% during the fourth quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock worth $162,731,000 after purchasing an additional 489,203 shares during the period. State Street Corp increased its stake in shares of Lantheus by 0.3% during the second quarter. State Street Corp now owns 2,393,559 shares of the medical equipment provider’s stock worth $158,047,000 after purchasing an additional 7,307 shares during the period. Hood River Capital Management LLC increased its stake in shares of Lantheus by 4.0% during the first quarter. Hood River Capital Management LLC now owns 1,633,626 shares of the medical equipment provider’s stock worth $134,872,000 after purchasing an additional 62,827 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Lantheus by 369.2% during the first quarter. Assenagon Asset Management S.A. now owns 1,454,887 shares of the medical equipment provider’s stock worth $120,115,000 after purchasing an additional 1,144,793 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

LNTH stock opened at $64.81 on Monday. The stock has a 50-day moving average price of $73.98 and a 200-day moving average price of $81.91. Lantheus Holdings, Inc. has a 1-year low of $47.46 and a 1-year high of $100.85. The company has a current ratio of 4.88, a quick ratio of 4.55 and a debt-to-equity ratio of 1.01. The firm has a market cap of $4.44 billion, a PE ratio of 158.07 and a beta of 0.68.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.17. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. The firm had revenue of $321.70 million during the quarter, compared to analyst estimates of $306.48 million. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 5.19 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on LNTH shares. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. StockNews.com began coverage on Lantheus in a report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, Truist Financial reaffirmed a “buy” rating and set a $125.00 target price on shares of Lantheus in a report on Friday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $121.83.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 1,752 shares of the stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the completion of the transaction, the chief accounting officer now directly owns 59,767 shares of the company’s stock, valued at $5,431,027.29. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CAO Andrea Sabens sold 1,752 shares of the firm’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total value of $159,204.24. Following the completion of the transaction, the chief accounting officer now directly owns 59,767 shares of the company’s stock, valued at $5,431,027.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mary Anne Heino sold 10,950 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $68.58, for a total value of $750,951.00. Following the completion of the transaction, the chief executive officer now directly owns 329,467 shares of the company’s stock, valued at $22,594,846.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,315 shares of company stock valued at $1,353,773. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.